{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:08:27Z","timestamp":1788944907203,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Nutr"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>Mild cognitive impairment (MCI) is characterized by a decline in cognitive functions while the ability to perform daily activities remains intact. This pathological condition is a recognized as risk factor for dementia-related disorders, and the current lack of therapies is the critical issue. Our preclinical studies indicated that a formulation (named GeNeurofil\u2122) exhibited a synergistic neuroprotective effect in an animal model of amyloid beta toxicity. Therefore, the present study aimed to evaluate the efficacy of GeNeurofil\u2122 in patients with mild cognitive impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/Methods<\/jats:title>\n                    <jats:p>A six-months, randomized, double-blind, placebo-controlled pilot trial (retrospectively registered on ISRCTN registry-number ISRCTN11405046-01\/07\/2026) was performed enrolling 54 patients with mild to moderate MCI (Clinical Dementia Rating Scale ranging from 0.5 to 2). Patients, concurrently maintained under their usual medications, received either the GeNeurofil\u2122 (0.7\u2009mL\u2009\u00d7\u20093\/day) or an identical placebo (0.7\u2009mL\u2009\u00d7\u20093\/day) for six months. The psychometric assessments were performed using the Mini Mental State Examination (MMSE) tests and depressive symptoms were evaluated with the Zung Test. Plasma samples were analyzed for NfL and p-TAU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After six months of treatment, GeNeurofil\u2122 supplementation improved CDR, MMSE, and Zung scores. Furthermore, the treatment reduced plasmatic levels of light neurofilaments (NfL) and phosphorylated Tau protein (p-TAU) compared to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our findings indicate that six months of supplementation with GeNeurofil\n                      <jats:sup>TM<\/jats:sup>\n                      might represent a helpful adjuvant strategy for cognitive impairment. GeNeurofil\u2122 nutraceutical supplementation demonstrates a favorable safety profile, however given the exploratory nature of this pilot feasibility trial, these preliminary findings will further followed by confirming definitive clinical efficacy in larger clinical trials.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41430-026-01791-6","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:18:45Z","timestamp":1785230325000},"page":"943-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of GeNeurofil\u2122 nutraceutical supplementation on psychometric assessment and biomarkers of neurodegeneration in cognitive impaired patients: a pilot study"],"prefix":"10.1038","volume":"80","author":[{"given":"Luigia","family":"Trabace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-5504","authenticated-orcid":false,"given":"Maria Grazia","family":"Morgese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7314-445X","authenticated-orcid":false,"given":"Paolo","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Pia","family":"Agosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ritrovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Gallotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Tolfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bevilacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"1791_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","volume":"11","author":"C Qiu","year":"2009","unstructured":"Qiu C, Kivipelto M, Von Strauss E. Epidemiology of Alzheimer\u2019s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11:111\u201328.","journal-title":"Dialogues Clin Neurosci"},{"key":"1791_CR2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1152\/physrev.00015.2020","volume":"101","author":"C Ferrari","year":"2021","unstructured":"Ferrari C, Sorbi S. The complexity of Alzheimer\u2019s disease: an evolving puzzle. Physiol Rev. 2021;101:1047\u201381.","journal-title":"Physiol Rev"},{"key":"1791_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.clinthera.2006.07.006","volume":"28","author":"A Levey","year":"2006","unstructured":"Levey A, Lah J, Goldstein F, Steenland K, Bliwise D. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer\u2019s disease. Clin Ther. 2006;28:991\u20131001.","journal-title":"Clin Ther"},{"key":"1791_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.tips.2024.01.012","volume":"45","author":"MK Sun","year":"2024","unstructured":"Sun MK, Alkon DL. Alzheimer\u2019s therapeutic development: shifting neurodegeneration to neuroregeneration. Trends Pharm Sci. 2024;45:197\u2013209.","journal-title":"Trends Pharm Sci"},{"key":"1791_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/imm.12922","volume":"154","author":"J Stephenson","year":"2018","unstructured":"Stephenson J, Nutma E, Van Der Valk P, Amor S. Inflammation in CNS neurodegenerative diseases. Immunology. 2018;154:204\u201319.","journal-title":"Immunology"},{"key":"1791_CR6","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.ajcnut.2023.04.001","volume":"117","author":"BZ Wei","year":"2023","unstructured":"Wei BZ, Li L, Dong CW, Tan CC, Xu W. The relationship of omega-3 fatty acids with dementia and cognitive decline: evidence from prospective cohort studies of supplementation, dietary intake, and blood markers. Am J Clin Nutr. 2023;117:1096\u2013109.","journal-title":"Am J Clin Nutr"},{"key":"1791_CR7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00702-020-02212-z","volume":"127","author":"K Yonezawa","year":"2020","unstructured":"Yonezawa K, Kusumoto Y, Kanchi N, Kinoshita H, Kanegae S, Yamaguchi N, et al. Recent trends in mental illness and omega-3 fatty acids. J Neural Transm. 2020;127:1491\u20139.","journal-title":"J Neural Transm"},{"key":"1791_CR8","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.3390\/nu15173848","volume":"15","author":"S P\u00e9rez-Pi\u00f1ero","year":"2023","unstructured":"P\u00e9rez-Pi\u00f1ero S, Mu\u00f1oz-Carrillo JC, Victoria-Montesinos D, Garc\u00eda-Mu\u00f1oz AM, Andreu-Caravaca L, G\u00f3mez M, et al. Efficacy of boswellia serrata extract and\/or an omega-3-based product for improving pain and function in people older than 40 years with persistent knee pain: a randomized double-blind controlled clinical trial. Nutrients. 2023;15:3848.","journal-title":"Nutrients"},{"key":"1791_CR9","first-page":"277","volume":"23","author":"A Rajabian","year":"2020","unstructured":"Rajabian A, Sadeghnia H, Fanoudi S, Hosseini A. Genus Boswellia as a new candidate for neurodegenerative disorders. Iran J Basic Med Sci. 2020;23:277\u201386.","journal-title":"Iran J Basic Med Sci"},{"key":"1791_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/biom11050686","volume":"11","author":"MG Morgese","year":"2021","unstructured":"Morgese MG, Bove M, Francavilla M, Schiavone S, Dimonte S, Colia AL, et al. Sublingual AKBA exerts antidepressant effects in the A\u03b2-treated mouse model. Biomolecules. 2021;11:686.","journal-title":"Biomolecules"},{"key":"1791_CR11","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.3390\/nu12102963","volume":"12","author":"HM Hashiesh","year":"2020","unstructured":"Hashiesh HM, Meeran MFN, Sharma C, Sadek B, Kaabi JA, Ojha SK. Therapeutic potential of \u03b2-caryophyllene: a dietary cannabinoid in diabetes and associated complications. Nutrients. 2020;12:2963.","journal-title":"Nutrients"},{"key":"1791_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81:255\u201363.","journal-title":"JAMA Neurol"},{"key":"1791_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-019-0472-5","volume":"11","author":"PSJ Weston","year":"2019","unstructured":"Weston PSJ, Poole T, O\u2019Connor A, Heslegrave A, Ryan NS, Liang Y, et al. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11:19.","journal-title":"Alzheimers Res Ther"},{"key":"1791_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery CJ, B\u00f6rjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023;29:1437\u201347.","journal-title":"Nat Med"},{"key":"1791_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1017\/S1041610297004870","volume":"9","author":"JC Morris","year":"1997","unstructured":"Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997;9:173\u20136. discussion 177\u2013178.","journal-title":"Int Psychogeriatr"},{"key":"1791_CR16","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/jcm9051537","volume":"9","author":"G Han","year":"2020","unstructured":"Han G, Maruta M, Ikeda Y, Ishikawa T, Tanaka H, Koyama A, et al. Relationship between performance on the mini-mental state examination sub-items and activities of daily living in patients with Alzheimer\u2019s disease. J Clin Med. 2020;9:1537.","journal-title":"J Clin Med"},{"key":"1791_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/02813432.2019.1639923","volume":"37","author":"J Jokelainen","year":"2019","unstructured":"Jokelainen J, Timonen M, Kein\u00e4nen-Kiukaanniemi S, H\u00e4rk\u00f6nen P, Jurvelin H, Suija K. Validation of the Zung self-rating depression scale (SDS) in older adults. Scand J Prim Health Care. 2019;37:353\u20137.","journal-title":"Scand J Prim Health Care"},{"key":"1791_CR18","doi-asserted-by":"publisher","first-page":"112250","DOI":"10.1016\/j.biopha.2021.112250","volume":"144","author":"A Siddiqui","year":"2021","unstructured":"Siddiqui A, Shah Z, Jahan RN, Othman I, Kumari Y. Mechanistic role of boswellic acids in Alzheimer\u2019s disease: emphasis on anti-inflammatory properties. Biomed Pharmacother. 2021;144:112250.","journal-title":"Biomed Pharmacother"},{"key":"1791_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.34172\/apb.2020.053","volume":"10","author":"A Jebelli","year":"2020","unstructured":"Jebelli A, Khalaj-Kondori M, Rahmati-Yamchi M. The effect of beta-boswellic acid on the expression of Camk4 and Camk2\u03b1 genes in the PC12 cell line. Adv Pharm Bull. 2020;10:437\u201343.","journal-title":"Adv Pharm Bull"},{"key":"1791_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10072-010-0220-x","volume":"31","author":"O Karima","year":"2010","unstructured":"Karima O, Riazi G, Yousefi R, Movahedi AAM. The enhancement effect of beta-boswellic acid on hippocampal neurites outgrowth and branching (an in vitro study). Neurol Sci. 2010;31:315\u201320.","journal-title":"Neurol Sci"},{"key":"1791_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cbi.2016.11.015","volume":"261","author":"NAG Santos","year":"2017","unstructured":"Santos NAG, Martins NM, Sisti FM, Fernandes LS, Ferreira RS, De Freitas O, et al. The cannabinoid beta-caryophyllene (BCP) induces neuritogenesis in PC12 cells by a cannabinoid-receptor-independent mechanism. Chem-Biol Interact. 2017;261:86\u201395.","journal-title":"Chem-Biol Interact"},{"key":"1791_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.joim.2024.01.007","volume":"22","author":"R Arnold","year":"2024","unstructured":"Arnold R, Murphy-Smith J, Ng CH, Mischoulon D, Byrne GJ, Bousman CA, et al. Predictors of the placebo response in a nutraceutical randomized controlled trial for depression. J Integr Med. 2024;22:46\u201353.","journal-title":"J Integr Med"},{"key":"1791_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/npp.2011.306","volume":"37","author":"J Undurraga","year":"2012","unstructured":"Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacol. 2012;37:851\u201364.","journal-title":"Neuropsychopharmacol"},{"key":"1791_CR24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, Costafreda SG, Selb\u00e6k G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404:572\u2013628.","journal-title":"Lancet"},{"key":"1791_CR25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/alz.12303","volume":"17","author":"W Yang","year":"2021","unstructured":"Yang W, Li X, Pan KY, Yang R, Song R, Qi X, et al. Association of life-course depression with the risk of dementia in late life: a nationwide twin study. Alzheimers Dement. 2021;17:1383\u201390.","journal-title":"Alzheimers Dement"},{"key":"1791_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5711","volume":"37","author":"J Stafford","year":"2022","unstructured":"Stafford J, Chung WT, Sommerlad A, Kirkbride JB, Howard R. Psychiatric disorders and risk of subsequent dementia: Systematic review and meta-analysis of longitudinal studies. Int J Geriat Psychiatry. 2022;37:gps.5711.","journal-title":"Int J Geriat Psychiatry"},{"key":"1791_CR27","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jamaneurol.2023.2309","volume":"80","author":"H Elser","year":"2023","unstructured":"Elser H, Horv\u00e1th-Puh\u00f3 E, Gradus JL, Smith ML, Lash TL, Glymour MM, et al. Association of early-, middle-, and late-life depression with incident dementia in a Danish cohort. JAMA Neurol. 2023;80:949\u201358.","journal-title":"JAMA Neurol"},{"key":"1791_CR28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.biopsych.2022.08.026","volume":"93","author":"L Yang","year":"2023","unstructured":"Yang L, Deng YT, Leng Y, Ou YN, Li YZ, Chen SD, et al. Depression, depression treatments, and risk of incident dementia: a prospective cohort study of 354,313 participants. Biol Psychiatry. 2023;93:802\u20139.","journal-title":"Biol Psychiatry"},{"key":"1791_CR29","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.biopsych.2023.10.008","volume":"95","author":"YY Huang","year":"2024","unstructured":"Huang YY, Gan YH, Yang L, Cheng W, Yu JT. Depression in alzheimer\u2019s disease: epidemiology, mechanisms, and treatment. Biol Psychiatry. 2024;95:992\u20131005.","journal-title":"Biol Psychiatry"},{"key":"1791_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.phrs.2017.11.034","volume":"129","author":"MG Morgese","year":"2018","unstructured":"Morgese MG, Schiavone S, Mhillaj E, Bove M, Tucci P, Trabace L. N-3 PUFA diet enrichment prevents amyloid beta-induced depressive-like phenotype. Pharm Res. 2018;129:526\u201334.","journal-title":"Pharm Res"}],"container-title":["European Journal of Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41430-026-01791-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41430-026-01791-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41430-026-01791-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:38:37Z","timestamp":1788943117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41430-026-01791-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1791"],"URL":"https:\/\/doi.org\/10.1038\/s41430-026-01791-6","relation":{},"ISSN":["0954-3007","1476-5640"],"issn-type":[{"value":"0954-3007","type":"print"},{"value":"1476-5640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We confirm the following regarding industry involvement and academic independence in this study: 1. Transparency of Funding: The industry funding for this project was transparent, acknowledged, and appropriately recognized throughout all stages of design, implementation, and reporting. 2. Academic Independence in Project Execution: Evidence is presented that the project design, implementation, analysis, and interpretation were performed with efforts to maximize academic independence in each of these areas. Specifically: Study Hypothesis: The initial study hypothesis was conceived primarily by the academic research team. Industry provided input on the practical feasibility and alignment with current market needs for the study\u2019s scope. The funder-affiliated co-author provided technical expertise on formulation\/logistics, however no involvement occurred in study design, recruitment, data collection, or independent statistical analysis\/interpretation. Study Design & Implementation: The detailed study design, including methodology, participant recruitment, data collection protocols, and intervention specifics, was developed by the academic team. Industry\u2019s involvement was limited to providing access to specific proprietary materials\/equipment and offering technical expertise regarding their use. An in kind contribution was provided only for the formulation and packaging of the nutraceutical and placebo, for laboratory reagents and kits, with no direct financial payments to the academic team. Data Analysis & Interpretation: All data analyses were conducted independently by the academic statisticians and researchers. Industry reviewed preliminary findings for factual accuracy, but had no influence on the statistical methods or the interpretation of the results. 3. Full Academic Independence to Report and Publish: We confirm full academic independence to report and publish all findings, irrespective of the outcome.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}